News & Updates

Assisted reproductive technology poses no excess risk of multiple sclerosis

01 Jan 2023

Exposure to assisted reproductive technology (ART) does not appear to promote the development of multiple sclerosis, a study has found.

Assisted reproductive technology poses no excess risk of multiple sclerosis

01 Jan 2023

Albumin confers survival benefit in select patients with cirrhosis

31 Dec 2022

Treatment with albumin appears to cut the risk of death in cirrhotic patients with spontaneous bacterial peritonitis or hepatic encephalopathy, with long-term treatment potentially lowering the risk of cirrhosis complications and need for paracentesis, according to the results of a meta-analysis.

Albumin confers survival benefit in select patients with cirrhosis

31 Dec 2022

Parkinson’s, T2D drug affords cardioprotection in youth with T1D

31 Dec 2022 by

Bromocriptine quick release, a medication used for Parkinson’s disease and type 2 diabetes (T2D), appears to confer cardiovascular benefits such as lower blood pressure (BP) and reduced aortic stiffness in teenagers with type 1 diabetes (T1D), according to data from the BCQR-T1D study.

Parkinson’s, T2D drug affords cardioprotection in youth with T1D

31 Dec 2022

$Parental astigmatism a risk factor for refractive, corneal astigmatism in children$

Parental astigmatism a risk factor for refractive, corneal astigmatism in children

31 Dec 2022

Children born to parents with astigmatism are likely to develop refractive or corneal astigmatism, according to a study, suggesting that parental astigmatism has an independent and dose-dependent association with child astigmatism.

Parental astigmatism a risk factor for refractive, corneal astigmatism in children

31 Dec 2022

Original New Drug Application Approvals by US FDA (16-31 December 2022)

31 Dec 2022

New drug applications approved by US FDA as of 16 - 31 December 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 December 2022)

31 Dec 2022

Semaglutide triumphs as an anti-obesity treatment for adolescents

30 Dec 2022 by

Adding a once-weekly dose of semaglutide to lifestyle intervention successfully reduced body mass index (BMI) in adolescents with obesity, according to results of the phase IIIa STEP TEENS trial.

Semaglutide triumphs as an anti-obesity treatment for adolescents

30 Dec 2022

Daunorubicin for newly diagnosed AML: Does more equate to better outcomes?

30 Dec 2022 by

In acute myeloid leukaemia (AML) patients who received the 7+3* induction, a higher daunorubicin dose or a double induction did not seem to yield better outcomes, findings from the two-part phase III SAL Dauno-Double trial suggest.

Daunorubicin for newly diagnosed AML: Does more equate to better outcomes?

30 Dec 2022

RAS inhibitor discontinuation of no help in slowing kidney decline

29 Dec 2022

Stopping treatment with renin–angiotensin system (RAS) inhibitors in patients with advanced chronic kidney disease does not appear to raise the levels of estimated glomerular filtration rate (eGFR) or decelerate its decline, according to a study.

RAS inhibitor discontinuation of no help in slowing kidney decline

29 Dec 2022

Heavy coffee drinking poses CVD mortality risk in presence of severe hypertension

29 Dec 2022 by

Individuals with severe hypertension may do well to refrain from drinking too much coffee, as it contributes to an increased risk of cardiovascular disease (CVD) death, a study has found.

Heavy coffee drinking poses CVD mortality risk in presence of severe hypertension

29 Dec 2022

Methotrexate boosts response to pegloticase for gout

29 Dec 2022

Co-treatment with methotrexate (MTX) appears to enhance response rates to pegloticase among patients with uncontrolled gout, according to a study.

Methotrexate boosts response to pegloticase for gout

29 Dec 2022

News & Updates

Filter by Specialty:

Specialty:

Assisted reproductive technology poses no excess risk of multiple sclerosis

Assisted reproductive technology poses no excess risk of multiple sclerosis

Albumin confers survival benefit in select patients with cirrhosis

Albumin confers survival benefit in select patients with cirrhosis

Parkinson’s, T2D drug affords cardioprotection in youth with T1D

Parkinson’s, T2D drug affords cardioprotection in youth with T1D

Parental astigmatism a risk factor for refractive, corneal astigmatism in children

Parental astigmatism a risk factor for refractive, corneal astigmatism in children

Original New Drug Application Approvals by US FDA (16-31 December 2022)

Original New Drug Application Approvals by US FDA (16-31 December 2022)

Semaglutide triumphs as an anti-obesity treatment for adolescents

Semaglutide triumphs as an anti-obesity treatment for adolescents

Daunorubicin for newly diagnosed AML: Does more equate to better outcomes?

Daunorubicin for newly diagnosed AML: Does more equate to better outcomes?

RAS inhibitor discontinuation of no help in slowing kidney decline

RAS inhibitor discontinuation of no help in slowing kidney decline

Heavy coffee drinking poses CVD mortality risk in presence of severe hypertension

Heavy coffee drinking poses CVD mortality risk in presence of severe hypertension

Methotrexate boosts response to pegloticase for gout

Methotrexate boosts response to pegloticase for gout